Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?
- 30 Downloads
Australian data regarding the management of patients with bronchiectasis is scarce. We sought to compare the management of adults with bronchiectasis attending tertiary Australian centres with recent national and international guidelines.
The Australian Bronchiectasis Registry is a centralised database of patients with radiologically confirmed bronchiectasis unrelated to cystic fibrosis recruited from 14 tertiary Australian hospitals. We excluded children (<18 years) and those with incomplete data, leaving 589 adults for cross-sectional analyses. We compared the proportion of patients receiving certain therapies, as compared to the proportion eligible for those treatments according to the current guidelines and baseline clinical information available from the registry.
Pulmonary rehabilitation was attended by 22%, although it was indicated in 67% of the cohort. Airway clearance was undertaken in 52% of patients, although 71% reported chronic productive cough. Sputum bacterial culture results were available for 59%, and mycobacterial culture results were available for 29% of the cohort. Inhaled antibiotics were used in half of potentially eligible patients. Despite guideline recommendations against routine use, inhaled corticosteroids were used in 48% of patients. Long-term macrolides were used in 28% of participants.
Discrepancies exist between guideline recommendations and real-world treatment of bronchiectasis in Australia, even in tertiary centres. These findings suggest the need for increased patient referral to pulmonary rehabilitation, increased attention to airway clearance, increased collection of sputum samples (especially for mycobacterial culture) and rationalisation of inhaled corticosteroid use. These findings encourage a review of treatment access and will inform ongoing education to promote evidence-based care for people living with bronchiectasis.
KeywordsBronchiectasis Treatment Guidelines Registry Australia
The Australian Bronchiectasis Registry is generously supported by the Australian Lung Foundation, Insmed Incorporated and the Zambon Group. Drs Bye, Burr, Chang, Holmes-Liew, King, Middleton, Maguire, Smith, Thomson and Morgan have been involved in clinical research related to bronchiectasis. Dr Chang is supported by a National Health and Medical Research Council (NHMRC) practitioner fellowship (Grant 1154302) and Dr Visser by a NHMRC post-graduate scholarship (Grant 1134081). Neither pharmaceutical company, nor any sponsoring or supporting body had any input to the interpretation of data or preparation of the manuscript.
- 1.Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS (2016) Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 47(1):186–193. https://doi.org/10.1183/13993003.01033-2015 CrossRefPubMedGoogle Scholar
- 3.Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J (2013) Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends. PLoS ONE 8(8):e71109. https://doi.org/10.1371/journal.pone.0071109 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Weycker D, Edelsberg J, Oster G, Tino G (2005) Prevalence and economic burden of bronchiectasis. Clin Pulm Med 12(4):205–209. https://doi.org/10.1097/01.cpm.0000171422.98696.ed CrossRefGoogle Scholar
- 10.Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J (2000) Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 162(2 Pt 1):481–485. https://doi.org/10.1164/ajrccm.162.2.9910086 CrossRefPubMedGoogle Scholar
- 11.Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG (2014) Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2(9):738–749. https://doi.org/10.1016/S2213-2600(14)70165-1 CrossRefPubMedGoogle Scholar
- 13.Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, van der Werf TS, Boersma WG (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309(12):1251–1259. https://doi.org/10.1001/jama.2013.1937 CrossRefPubMedGoogle Scholar
- 14.Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309(12):1260–1267. https://doi.org/10.1001/jama.2013.2290 CrossRefPubMedGoogle Scholar
- 15.Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T (2012) Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380(9842):660–667. https://doi.org/10.1016/S0140-6736(12)60953-2 CrossRefPubMedGoogle Scholar
- 17.Zhuo G-Y, He Q, Xiang-Lian L, Ya-Nan Y, Si-Te F (2014) Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Pulm Pharmacol Ther 29(1):80–88. https://doi.org/10.1016/j.pupt.2014.02.002 CrossRefPubMedGoogle Scholar
- 18.Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R (2018) RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 51(1):1702053. https://doi.org/10.1183/13993003.02053-2017 CrossRefPubMedGoogle Scholar
- 19.De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R (2018) RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J 51(1):1702052CrossRefGoogle Scholar
- 20.Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE (2019) Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir MedGoogle Scholar
- 22.Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJA, O'Dochartaigh C, van Haren EHJ, Vidal LO, Welte T, Fox HG, Wu J, Charlton B, Investigators BS (2014) Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 69(12):1073–1079. https://doi.org/10.1136/thoraxjnl-2014-205587 CrossRefPubMedGoogle Scholar
- 23.Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O’Mara P, Grimwood K, Alison J, Cull C, Currie B, Gardner I, Holmes P, Hunter C, Kolbe J, Maclennan C, McDonald M, Morris P, Nicolson C, Petsky H, Pillarisetti N, Reynolds E, Serisier D, Thein F, van Asperen P, Voss L, Wong C (2015) Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 202(1):21–24. https://doi.org/10.5694/mja14.00287 CrossRefPubMedGoogle Scholar
- 27.Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT (2014) The bronchiectasis severity index an international derivation and validation study. Am J Respir Crit Care Med 189(5):576–585. https://doi.org/10.1164/rccm.201309-1575OC CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Walker P, Herrero B, Spinou A, Dimakou K, Blasi F, Ringshausen F, De Soyza A, Vendrell M, Goeminne P, Boersma W (2018) Variability in access and referral to pulmonary rehabilitation in European bronchiectasis patients enrolled in the EMBARC registry. Eur Respiratory Soc.Google Scholar
- 33.Lee AL, Burge AT, Holland AE (2015) Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 11:CD008351Google Scholar
- 39.Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT (2012) Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 186(7):657–665. https://doi.org/10.1164/rccm.201203-0487OC CrossRefPubMedGoogle Scholar
- 41.Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ (2018) Characterization of the "frequent exacerbator phenotype" in Bronchiectasis. Am J Respir Crit Care Med 197(11):1410–1420. https://doi.org/10.1164/rccm.201711-2202OC CrossRefPubMedGoogle Scholar
- 42.Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA (2017) British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72:1–64. https://doi.org/10.1136/thoraxjnl-2017-210927 CrossRefGoogle Scholar
- 44.Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB (2018) Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev 5:CD000996Google Scholar
- 45.Polverino E, Dimakou K, Hurst J, Martinez-Garcia M-A, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD (2018) The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J 52(3):1800328. https://doi.org/10.1183/13993003.00328-2018 CrossRefPubMedGoogle Scholar
- 47.Global Initiative for Asthma (2017) Global strategy for asthma management and prevention.Google Scholar